Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | July 07, 2023 | July 11, 2023 |
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| TETRAPHASE PHARMACEUTICALS INCTTPH · Entity 147285 | Director | June 10, 2019 | June 11, 2019 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Commercial Officer | May 14, 2012 | June 01, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date July 07, 2023 · Filed July 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,356 |
Ending reported balance
After 2023-07-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-07-07 · Exercise / conversion · Acquired 5,957 · Balance 21,786 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2023-07-07 · Tax withholding · Disposed 1,430 · Balance 20,356 |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-07-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-07-07 · Exercise / conversion · Disposed 5,957 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F3: This award is fully vested in accordance with its terms. |
| Ordinary SharesSEC Table I · non-derivative | IndirectThe Nancy J. Wysenski Revocable Trust | 11,242 |
Reported balance
Holding disclosure · report date 2023-07-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 11,242 F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust"). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: The reporting person is a trustee and a beneficiary of The Nancy J. Wysenski Revocable Trust, established on September 23, 2014 ("The Nancy J. Wysenski Revocable Trust").
F3: This award is fully vested in accordance with its terms.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,992 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 75 · Balance 33,992 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
TETRAPHASE PHARMACEUTICALS INC
Report date June 10, 2019 · Filed June 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2029-06-09 | Direct | 16,500 |
Reported balance
After 2019-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-10 · Grant · Acquired 16,500 · Balance 16,500 F1: Vests in equal quarterly installments over a one-year period measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in equal quarterly installments over a one-year period measured from the date of grant.
VERTEX PHARMACEUTICALS INC / MA
Report date May 14, 2012 · Filed June 01, 2012 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,232 |
Last balance in matching sequence
After 2012-05-14 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2012-05-14 · Sale · Disposed 179,628 · Balance 32,604 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82). F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 2 · 2012-05-14 · Sale · Disposed 372 · Balance 32,232 F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Amended to delete a prior footnote that indicated, due to a clerical error by the company, that these transactions were pursuant to a Rule 10b5-1 plan. The Form 144 filed with the SEC in connection with the transactions accurately noted that the sales were not conducted under a Rule 10b5-1 plan.
F2: Open market sales reported on this line occurred at a weighted average price of $64.27 (range $63.90 to $64.82).
F3: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dova Pharmaceuticals Inc.
Report date November 12, 2019 · Filed November 12, 2019
Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 1
1 source rowRow 1 · 2019-11-12 · Disposition to issuer · Disposed 6,274 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.36 · Expires 2029-04-25 | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-12 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
F2: This option, which provided for vesting monthly over one year from the grant date and in any event will be fully vested on the date of the next annual meeting of our stockholders, was accelerated and canceled in the Merger in exchange for a cash payment of $181,400.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
Provention Bio, Inc.
Report date April 27, 2023 · Filed April 27, 2023
Section 16 reporting ended · disclosed 2023-04-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.16 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-27 · Disposition to issuer · Disposed 128,981 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.62 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-04-27 · Disposition to issuer · Disposed 22,200 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.80 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-27 · Disposition to issuer · Disposed 23,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $4.52 | Direct | 0 |
Reported balance
After 2023-04-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-04-27 · Disposition to issuer · Disposed 33,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 12, 2023, by and among the Issuer, Sanofi S.A. ("Parent"), and Zest Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer (the "Merger") effective as of April 27, 2023 (the "Effective Time"). Pursuant to the actions of the board of directors of the Issuer and in accordance with the terms of the Merger Agreement, at the Effective Time, each option to purchase shares of Company Common Stock granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full.
F2: As of the Effective Time, each Company Stock Option that was outstanding and vested immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option became entitled to receive in consideration of the cancellation of such Company Stock Option, an amount in cash (without interest and less applicable tax withholdings) equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $25.00 over the applicable exercise price per share of Company Common Stock under such Company Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 18,750 | $63.52 | $1,191,000.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 11 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,394 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,196 | $62.08 | $632,967.68 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 10 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,144 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 9,063 | $59.19 | $536,438.97 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 9 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,340 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 18,750 | $39.70 | $744,375.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 8 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,196 | $38.80 | $395,604.80 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 7 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 9,063 | $33.82 | $306,510.66 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 6 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,457 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 3,398 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 15 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,977 Underlying: Common Stock · 3,398 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 120,000 | $0.00 Strike: $39.70 | $0.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 14 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 120,000 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 12,500 | $0.00 Strike: $39.70 | $0.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 13 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,500 shares Expires 2019-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 6,797 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · derivative · entry 12 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,453 Underlying: Common Stock · 6,897 shares Expires 2020-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 147,695 | $54.50 | $8,049,377.50 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 5 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,394 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,398 | $38.80 | $131,842.40 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 4 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,089 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 120,000 | $39.70 | $4,764,000.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 3 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 12,500 | $39.70 | $496,250.00 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2012 Filed May 9, 2012 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 6,797 | $33.82 | $229,874.54 |
DisclosureSEC source: 0001209191-12-027021 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 72,500 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-12-007784 · doc4.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 72,500 shares Expires 2022-02-01 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2012 Filed Feb 6, 2012 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 14,501 | $0.01 | $145.01 |
DisclosureSEC source: 0001209191-12-007784 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,394 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. Read SEC document |
| January 19, 2012 Filed Jan 23, 2012 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,042 | $37.00 | $223,554.00 |
DisclosureSEC source: 0001209191-12-004858 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,893 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $37.00 (range $36.85 to $37.10). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2011 Filed Dec 13, 2011 22:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $28.90 | $144,500.00 |
DisclosureSEC source: 0001209191-11-061087 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,935 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $28.90 (range $28.75 to $29.17). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 15, 2011 Filed Nov 16, 2011 19:47 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 606 | $29.77 | $18,040.62 |
DisclosureSEC source: 0001209191-11-056355 · doc4.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,935 F1 · kind: Transaction made pursuant to Ms. Wysenski's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $29.77 (range $29.65 to $29.95). F3 · price: Ms. Wysenski undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 13, 2011 Filed Jul 14, 2011 19:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 36,250 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-11-039521 · doc4.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2021-07-12 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/13/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 54,375 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0000875320-11-000012 · edgar.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,375 Underlying: Common Stock · 54,375 shares Expires 2021-02-02 F2 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/03/2011. Read SEC document |
| February 03, 2011 Filed Feb 7, 2011 19:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 12,084 | $0.01 | $120.84 |
DisclosureSEC source: 0000875320-11-000012 · edgar.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,084 F1 · shares: Stock grant under 2006 Stock and Option Plan, vesting on 2/3/2015, subject to (i) earlier acceleration of 50% of shares upon (A) receiving U.S. and E.U. marketing approval for VX-770 or (B) reaching specified telaprevir sales levels during 18 months following its U.S. launch; and (ii) earlier acceleration of 50% of shares upon (1) acceptance by the FDA of an NDA for a treatment regimen that includes telaprevir and VX-222; (2) initiation of a pivotal trial for a drug candidate for which the Company has U.S. commercialization rights in an indication that is not HCV infection or CF; or (3) reaching specified telaprevir sales levels during 18 months following its U.S. launch. Read SEC document |
| July 14, 2010 Filed Jul 16, 2010 19:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Options · Derivative | 36,250 | $0.00 Strike: $33.82 | $0.00 |
DisclosureSEC source: 0000875320-10-000042 · edgar.xml · derivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2020-07-13 F1 · derivative.exercise_date: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 07/14/2010. Read SEC document |
| December 09, 2009 Filed Dec 11, 2009 17:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 300,000 | $0.00 Strike: $39.70 | $0.00 |
DisclosureSEC source: 0000875320-09-000108 · primary_doc.xml · derivative · entry 3 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2019-12-08 F3 · shares: Stock option under 2006 Stock and Option Plan, vesting on 10/22/2014, subject to 20% acceleration upon receiving U.S. marketing approval for telaprevir; up to an additional 40% acceleration upon receiving U.S. approval for telaprevir if certain other performance goals are achieved; and acceleration of remaining unvested shares upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012. Read SEC document |
| December 09, 2009 Filed Dec 11, 2009 17:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 100,000 | $0.00 Strike: $39.70 | $0.00 |
DisclosureSEC source: 0000875320-09-000108 · primary_doc.xml · derivative · entry 2 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2019-12-08 F2 · shares: Right to buy under 2006 Stock and Option Plan, vesting in 16 equal installments over four years. Read SEC document |
| December 09, 2009 Filed Dec 11, 2009 17:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 20,000 | $0.01 | $200.00 |
DisclosureSEC source: 0000875320-09-000108 · primary_doc.xml · nonDerivative · entry 1 Wysenski Nancy · CIK 0001294596 · EVP & Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Stock grant made under 2006 Stock and Option Plan Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.